Lisata Therapeutics is no longer a going-concern oncology developer in any practical sense; after Kuva Labs failed to fund a tender that had already been cut from a five-dollar cash bid to a four-dollar cash bid plus contingent rights, the equity is a residual claim on a shrinking cash pile and a single peptide whose Phase Three readiness work has been paused.
The failed Kuva Labs tender is the event that rewrites the equity. Kuva, a privately held imaging company with no commercial oncology franchise, signed a merger in early spring that promised cash at closing plus a contingent value right tied to certepetide regulatory filings, then repeatedly amended the cash component down and still could not raise the money to accept tendered shares when the offer expired in late July. Lisata terminated the agreement days later, told the market that the depositary was returning every share, and opened a case in the Delaware Court of Chancery seeking a $2 million termination fee plus damages. The same filing that describes that claim also warns that Kuva may lack assets to satisfy a judgment and that Lisata has limited funds to prosecute the case, which is the mechanism that converts a headline breakup fee into an uncollected receivable. Shareholders who had priced the name as a take-private with a cash floor instead received their stock back and a litigation stub.
The tension is that the same board that recommended the tender is now running a liquidation-adjacent review while cash drains and the operating franchise is being dismantled. A workforce cut of 72 percent took effect in early August, the chief medical officer was dismissed without cause, and Phase Three chemistry and manufacturing readiness for metastatic pancreatic cancer was already delayed to conserve capital. Cash sat near $10 million at mid-year after a first-half operating drain that left little room for error. The August severance charge of roughly $1 million hits the third quarter before any run-rate savings appear. Management states there is substantial doubt about continuing as a going concern for twelve months after issuance, and the strategic-alternatives list explicitly includes asset sales, reverse merger, and liquidation. That is not a temporary pause in a platform build. It is the residual-value phase of a clinical-stage company that spent the first half of the year paying lawyers to close a deal that never funded.
What resolves the name is not a new internal trial readout. It is whether the strategic review produces a buyer or reverse-merger partner for certepetide before cash and listing pressure force a thinner outcome, and whether the Delaware action actually collects the termination fee.